Covance’s early development facility in Shanghai, China, has received GLP Certificate from the State Food and Drug Administration (SFDA) of the People’s Republic of China. The facility in Shanghai provides nonclinical safety assessment, bioanalytical, in vivo pharmacology, and DMPK services.
 
“Covance is now the only global CRO with SFDA GLP certification in China. Our early development facility in Shanghai offers world-class quality and expertise to companies with testing needs in China and the Asia Pacific region. Partnering with Covance in China will provide the gateway for local and regional pharmaceutical companies to access global markets and help save clients’ time and costs in their drug development process,” said Honggang Bi, corporate vice president and general manager, Covance China.